CoChat
Sign Up
Cited by 3,877

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Comprehensive genomic characterization of head and neck squamous cell carcinomas

The Cancer Genome Atlas Network·2015·Nature
DOI 10.1038/nature14129PMC PMC4311405
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature14129

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DNA copy number alterations. a, Copy number alterations by anatomic site and HPV status for squamous cancers. Lung squamous cell carcinoma (LUSC, n = 358) and cervical squamous cell carcinoma (CESC, n = 114). b, Unsupervised analysis of copy number alteration of HNSCC (n = 279) with associated characteristics. The rectangle indicates chromosome 7 amplifications in the purple cluster. NA, not available. PowerPoint slide
Figure 1 DNA copy number alterations. a, Copy number alterations by anatomic site and HPV status for squamous cancers. Lung squamous cell carcinoma (LUSC, n = 358) and cervical squamous cell carcinoma (CESC, n = 114). b, Unsupervised analysis of copy number alteration of HNSCC (n = 279) with associated characteristics. The rectangle indicates chromosome 7 amplifications in the purple cluster. NA, not available. PowerPoint slideCC BY-NC-SA · PubMed Central
Figure 2 Significantly mutated genes in HNSCC. Genes (rows) with significantly mutated genes (identified using the MutSigCV algorithim; q < 0.1) ordered by q value; additional genes with trends towards significance are also shown. Samples (columns, n = 279) are arranged to emphasize mutual exclusivity among mutations. Left, mutation percentage in TCGA. Right, mutation percentage in COSMIC (‘upper aerodigestive tract’ tissue). Top, overall number of mutations per megabase. Colour coding indicates mutation type. PowerPoint slide
Figure 2 Significantly mutated genes in HNSCC. Genes (rows) with significantly mutated genes (identified using the MutSigCV algorithim; q < 0.1) ordered by q value; additional genes with trends towards significance are also shown. Samples (columns, n = 279) are arranged to emphasize mutual exclusivity among mutations. Left, mutation percentage in TCGA. Right, mutation percentage in COSMIC (‘upper aerodigestive tract’ tissue). Top, overall number of mutations per megabase. Colour coding indicates mutation type. PowerPoint slideCC BY-NC-SA · PubMed Central
Figure 3 Candidate therapeutic targets and driver oncogenic events. Alteration events for key genes are displayed by sample (n = 279). TSG, tumour suppressor gene. PowerPoint slide
Figure 3 Candidate therapeutic targets and driver oncogenic events. Alteration events for key genes are displayed by sample (n = 279). TSG, tumour suppressor gene. PowerPoint slideCC BY-NC-SA · PubMed Central
Figure 4 Integrated analysis of genomic alterations. a, b, Samples (n = 279) are displayed in columns and grouped by gene expression (a) or methylation (b) subtype (sub.). Unadjusted two-sided Fisher’s exact test P values assess the association of each genomic alteration. Methylation probe location of CpG islands, shores and shelves are shown on the left of b. Annotation shows HPV status and subtype (16, 33 and 35). CN, copy number. PowerPoint slide
Figure 4 Integrated analysis of genomic alterations. a, b, Samples (n = 279) are displayed in columns and grouped by gene expression (a) or methylation (b) subtype (sub.). Unadjusted two-sided Fisher’s exact test P values assess the association of each genomic alteration. Methylation probe location of CpG islands, shores and shelves are shown on the left of b. Annotation shows HPV status and subtype (16, 33 and 35). CN, copy number. PowerPoint slideCC BY-NC-SA · PubMed Central
Figure 5 Deregulation of signalling pathways and transcription factors. Key affected pathways, components and inferred functions, are summarized in the main text and Supplementary Information section 7 for n = 279 samples. The frequency (%) of genetic alterations for HPV(−) and HPV(+) tumours are shown separately within sub-panels and highlighted. Also see Supplementary Fig. 7.15. Pathway alterations include homozygous deletions, focal amplifications and somatic mutations. Activated and inactivated pathways/genes, and activating or inhibitory symbols are based on predicted effects of genome alterations and/or pathway functions. PowerPoint slide
Figure 5 Deregulation of signalling pathways and transcription factors. Key affected pathways, components and inferred functions, are summarized in the main text and Supplementary Information section 7 for n = 279 samples. The frequency (%) of genetic alterations for HPV(−) and HPV(+) tumours are shown separately within sub-panels and highlighted. Also see Supplementary Fig. 7.15. Pathway alterations include homozygous deletions, focal amplifications and somatic mutations. Activated and inactivated pathways/genes, and activating or inhibitory symbols are based on predicted effects of genome alterations and/or pathway functions. PowerPoint slideCC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 43

  1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010) · DOI
  2. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35 (2010) · DOI
  3. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011) · DOI
  4. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154–1157 (2011) · DOI
  5. Oganesyan, G. et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439, 208–211 (2006) · DOI
  6. Karim, R. et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte’s innate immune response. PLoS Pathog. 9, e1003384 (2013) · DOI
  7. Eliopoulos, A. G. et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein–Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13, 2243–2254 (1996)
  8. Imbeault, M. et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J. Virol. 85, 2189–2200 (2011) · DOI
  9. Ni, C. Z. et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc. Natl Acad. Sci. USA 97, 10395–10399 (2000) · DOI
  10. Chung, G. T. et al. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J. Pathol. 231, 311–322 (2013) · DOI
  11. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007) · DOI · Paper page
  12. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nature Genet. 45, 1127–1133 (2013) · DOI
  13. Smeets, S. J. et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cellular Oncol. 31, 291–300 (2009)
  14. Mayo, M. W. et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812–1815 (1997) · DOI
  15. Sok, J. C. et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12, 5064–5073 (2006) · DOI
  16. Kong-Beltran, M. et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283–289 (2006) · DOI
  17. Popescu, N. C., DiPaolo, J. A. & Amsbaugh, S. C. Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet. Cell Genet. 44, 58–62 (1987) · DOI
  18. Forbes, S. A. et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. Chapter 10, Unit 10.11 (2008)
  19. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001) · DOI · Paper page
  20. Morris, L. G. et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genet. 45, 253–261 (2013) · DOI
  21. Haraguchi, K. et al. Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3β-mediated phosphorylation of β-catenin. Oncogene 27, 274–284 (2008) · DOI
  22. Nagai, Y. et al. The LIM protein Ajuba is required for ciliogenesis and left-right axis determination in medaka. Biochem. Biophys. Res. Commun. 396, 887–893 (2010) · DOI
  23. Sun, G. & Irvine, K. D. Ajuba family proteins link JNK to Hippo signaling. Sci. Signal. 6, ra81 (2013)
  24. Reddy, B. V. & Irvine, K. D. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev. Cell 24, 459–471 (2013) · DOI
  25. Kalan, S., Matveyenko, A. & Loayza, D. LIM protein Ajuba participates in the repression of the ATR-mediated DNA damage response. Front. Genet. 4, 95 (2013) · DOI
  26. Nola, S. et al. Ajuba is required for Rac activation and maintenance of E-cadherin adhesion. J. Cell Biol. 195, 855–871 (2011) · DOI
  27. Fickie, M. R. et al. Adults with Sotos syndrome: review of 21 adults with molecularly confirmed NSD1 alterations, including a detailed case report of the oldest person. Am. J. Med. Genet. A. 155, 2105–2111 (2011) · DOI
  28. Wang, G. G., Cai, L., Pasillas, M. P. & Kamps, M. P. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nature Cell Biol. 9, 804–812 (2007) · DOI
  29. Quintana, R. M. et al. A transposon-based analysis of gene mutations related to skin cancer development. J. Invest. Dermatol. 133, 239–248 (2013) · DOI
  30. Chung, C. H. et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489–500 (2004) · DOI · Paper page
  31. Walter, V. et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE 8, e56823 (2013) · DOI
  32. Lu, S. L. et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331–1342 (2006) · DOI
  33. Oberst, A. & Green, D. R. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nature Rev. Mol. Cell Biol. 12, 757–763 (2011) · DOI
  34. Park, S. J. et al. Opposite role of Ras in tumor necrosis factor-α-induced cell cycle regulation: competition for Raf kinase. Biochem. Biophys. Res. Commun. 287, 1140–1147 (2001) · DOI
  35. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279–290 (2013) · DOI · Paper page
  36. Wong, J. V., Dong, P., Nevins, J. R., Mathey-Prevot, B. & You, L. Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle 10, 3086–3094 (2011) · DOI
  37. Sanhaji, M. et al. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle 12, 1340–1351 (2013) · DOI
  38. Morishita, A. et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 73, 4289–4299 (2013) · DOI
  39. Bancroft, C. C. et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer 99, 538–548 (2002) · DOI
  40. Yang, X. et al. ΔNp63 versatilely regulates a broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 71, 3688–3700 (2011) · DOI
  41. Keating, P. J. et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer 72, 405–411 (1995) · DOI
  42. Esteban, F. et al. Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br. J. Cancer 62, 1047–1051 (1990) · DOI
  43. Dotto, G. P. Crosstalk of Notch with p53 and p63 in cancer growth control. Nature Rev. Cancer 9, 587–595 (2009) · DOI

Cited by

See all 3,877

Metadata

Authors
The Cancer Genome Atlas Network
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2015-01-28
Volume
517
Issue
7536
Pages
576-582
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/nature14129
PMC
PMC4311405
Cited by
3,877
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review